Osteosarcoma - Pipeline Insight, 2024

This “Osteosarcoma - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteosarcoma Understanding

Osteosarcoma: Overview

A “Sarcoma” is a type of cancer that that develops in connective tissue such as bone, cartilage, or muscle and “Osteo” refers to bones. Osteosarcoma or osteogenic sarcoma is a type of cancer that starts in the bones. Osteosarcoma is a rare type of bone cancer in which malignant (cancerous) cells produce irregular bone. Although osteosarcoma can affect people of all ages, it most often occurs in children and teens who are still growing. The tumor usually develops at the ends of the long bones, specifically around the knee and in the shoulder, but can occur anywhere in the body. The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. Pain is the most common symptom of osteosarcoma. This pain may come and go at first but, gradually, it becomes constant. Some patients may have swelling or a mass in the area of the tumor. If the tumors are in the bones of your legs, it may cause limping. However, osteosarcomas can also be painless. Treatment usually involves chemotherapy, surgery and, sometimes, radiation therapy. Diagnosis is based upon medical history and physical examination; imaging tests like X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy.

Osteosarcoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteosarcoma pipeline landscape is provided which includes the disease overview and Osteosarcoma treatment guidelines. The assessment part of the report embraces, in depth Osteosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Osteosarcoma.

Osteosarcoma Emerging Drugs Chapters

This segment of the Osteosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteosarcoma Emerging Drugs

ZKAB-001: Lee’s Pharmaceutical ZKAB001 is a fully human anti-PD-L1 monoclonal antibody targeting tumor PD-L1 protein. It can release the “brake” causing by the tumor cell to the immune system. A phase I clinical trial in osteosarcoma patients who underwent upfront therapy to evaluate whether ZKAB001 can prevent tumor recurrence was completed early this year and the encouraging results therefrom has led to the initiation of this phase III clinical trial titled “Study of ZKAB001 for Maintenance Therapy in Patients with High-grade Osteosarcoma after AdjuvantChemotherapy”.

Lenvatinib: Eisai Co Ltd/Merck & Co Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRa), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. Currently it is being investigated in Phase II stage of development to provide the potential treatment for the patients withosteosarcoma.

ZN c3: Zentalis Pharmaceuticals ZN-c3 is a combination with gemcitabine used in adult and pediatric subjects with relapsed or refractory osteosarcoma. ZN-c3 is a phase I/II drug, developed by Zentalis Pharmaceuticals. ZN-c3 drug is an investigational drug and gemcitabine is an approved drug. ZN-c3 have received a fast track designation for uterine cancer but is under phase I/II for osteosarcoma.

Osteosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Osteosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteosarcoma

There are approx. 30+ key companies which are developing the therapies for Osteosarcoma. The companies which have their Osteosarcoma drug candidates in the most advanced stage, i.e. phase III include, Lee’s Pharmaceutical

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteosarcoma drugs.

Osteosarcoma Report Insights

• Osteosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteosarcoma drugs?
• How many Osteosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AlaMab Therapeutics
• Zentalis Pharmaceuticals
• Merck Eprova
• Eisai Co Ltd
• George Clinical Pty Ltd
• Y-mAbs Therapeutics
• Jiangsu Hengrui Medicine
• AstraZeneca
• Advenchen Laboratories LLC
• Innovent Biologics
• PersonGen Bio Therapeutics(Suzhou)
• Cellectar Biosciences, Inc.
• Merck & Co
• Hutchison Medipharma Limited
• MacroGenics
• Gradalis, Inc.
• Shanghai Pharmaceuticals Holding
• Celgene
• Oncternal Therapeutics
• Valent Technologies

Key Products

• ALMB 0168
• ZN c3
• Arfolitixorin - Isofol Medical
• Lenvatinib
• OST31-164
• Nivatrotamab
• Camrelizumab
• Ceralasertib
• Rivoceranib
• Humanized anti-GD2 antibody
• Targeting CD276 CAR T cells
• CLR- 131
• Pembrolizumab
• Surufatinib
• Enoblituzumab
• Vigil
• TK216
• Iodine I 131 MOAB 8H9
• Durvalumab
• TK216
• VAL-413

This product will be delivered within 1-3 business days.